Date: 2017-05-01
Type of information: Submission of a clinical trial application
phase: 1
Announcement: submission of a clinical trial application
Company: Tesaro (US - MA)
Product: TSR-033
Action mechanism: monoclonal antibody/immune checkpoint inhibitor. TSR-033 is a monoclonal antibody candidate targeting LAG-3 developed as part of collaboration between Tesaro and AnaptysBio. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drugs targeting PD-1, TIM-3 (TSR-022), and LAG-3 (TSR-033), in addition to a bi-specific antibody drug candidate targeting PD-1/LAG-3.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news:
